AN2 Therapeutics Inc (ANTX)
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics. Its lead candidate, epetraborole, is being evaluated in a phase 3 trial as a once-daily oral treatment for non-tuberculous mycobacterial lung disease and is also under study for acute melioidosis. The company is also advancing AN2-502998 (AN15368), a boron-based investigational compound in preclinical development for chronic Chagas disease, alongside additional research programs in oncology and infectious disease built around its boron chemistry platform. AN2 Therapeutics holds collaboration and license agreements with Anacor Pharmaceuticals, Brii Biosciences Limited, and GSK plc related to the development and commercialization of selected compounds, including epetraborole. Incorporated in 2017, the company is headquartered in Menlo Park, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ANTX
|
$3.48
|
-29.6% Downside
|
Overvalued
|
$9
|
82.2% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-5.2x
|
2.2x
|
—
|
172.9 M
|
93.352 M
|
0.0%
|
55.5%
|
13.8
|
—
|
90.5%
|
